Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fidaxomicin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DIFICLIR (fidaxomicin) is a macrolide antibacterial medicine indicated as an initial treatment and first recurrence of Clostridioides difficile infection. Fidaxomicin treats CDI with minimal disruption to the microbiota, helping to preserve colonisation ...
Product Name : Dificlir
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
July 12, 2021
Lead Product(s) : Fidaxomicin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fidaxomicin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tillotts Pharma AG Continues Growth With Launch In Belgium, The Netherlands And Luxembourg
Details : Dificlir is an anti-toxin which contains the dynamic substance fidaxomicin used for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients.
Product Name : Dificlir
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
May 20, 2021
Lead Product(s) : Fidaxomicin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fidaxomicin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Astellas Pharma
Deal Size : $130.3 million
Deal Type : Agreement
Astellas Transfers Dificlir in Europe, Middle East, Africa and selected CIS to Tillotts Pharma
Details : Under the agreement, Astellas Europe will transfer its marketing authorizations for Dificlirtm (generic name: fidaxomicin) tablets for Clostridium difficile infections in Europe, Middle East, Africa and selected Commonwealth of Independent States to Till...
Product Name : Dificlir
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
November 27, 2020
Lead Product(s) : Fidaxomicin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Astellas Pharma
Deal Size : $130.3 million
Deal Type : Agreement
Lead Product(s) : Metronidazole Benzoate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Swiss Commission for Technology and Innovation | University of Basel | University Hospital, Basel | SocraTec R&D GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmaco-Scintigraphic Study to Evaluate the Release Profile of Metronidazole Benzoate Capsules
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 22, 2016
Lead Product(s) : Metronidazole Benzoate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Swiss Commission for Technology and Innovation | University of Basel | University Hospital, Basel | SocraTec R&D GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TP0501 - Pharmaco-Scintigraphic-Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 03, 2014
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TP0502-Pharmaco-Scintigraphic-Study and Amendment
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 03, 2014
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TP0502-B-Pharmaco-Scintigraphic-Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 03, 2014
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mesalazine
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Recipient : Tehran University of Medical Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Mesalamine and Amitriptyline on Irritable Bowel Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 15, 2014
Lead Product(s) : Mesalazine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Recipient : Tehran University of Medical Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 19, 2013
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Zeria Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis
Details : Undisclosed
Product Name : Asacol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 09, 2010
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Zeria Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
